KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Receivables - Net: 2013-2024

Historic Receivables - Net for Xenon Pharmaceuticals (XENE) over the last 11 years, with Dec 2024 value amounting to $1.5 million.

  • Xenon Pharmaceuticals' Receivables - Net rose 938.30% to $8.6 million in Q1 2025 from the same period last year, while for Mar 2025 it was $8.6 million, marking a year-over-year increase of 938.30%. This contributed to the annual value of $1.5 million for FY2024, which is 68.08% up from last year.
  • Latest data reveals that Xenon Pharmaceuticals reported Receivables - Net of $1.5 million as of FY2024, which was up 68.08% from $874,000 recorded in FY2023.
  • In the past 5 years, Xenon Pharmaceuticals' Receivables - Net registered a high of $2.8 million during FY2021, and its lowest value of $874,000 during FY2023.
  • Its 3-year average for Receivables - Net is $1.1 million, with a median of $986,000 in 2022.
  • As far as peak fluctuations go, Xenon Pharmaceuticals' Receivables - Net soared by 124.11% in 2020, and later tumbled by 64.34% in 2022.
  • Xenon Pharmaceuticals' Receivables - Net (Yearly) stood at $1.8 million in 2020, then surged by 51.76% to $2.8 million in 2021, then tumbled by 64.34% to $986,000 in 2022, then dropped by 11.36% to $874,000 in 2023, then surged by 68.08% to $1.5 million in 2024.